



Our Fight with Cancer is Personal.

Arming cells. Against cancer. For good.



We are a cell therapy company working to redefine cancer treatment.

We know every cancer journey is personal, and for us, it's personal too. From our commitment to scientific innovation to our perseverance in the development, commercialization and delivery of innovative cell therapies, Adaptimmune is committed to redefining the treatment of cancer. Our proprietary cell therapy platform exemplifies this personalized approach with autologous cell therapies that start with a patient's own cells.



About Adaptimmune's cell therapies

We use cell therapies to tackle difficult-to-treat solid tumor cancers by engineering a person's own T cells to fight their cancer in a single-dose treatment. With our first TCR T-cell therapy now FDA approved and multiple studies underway exploring the application of our single-dose cell therapies in additional solid tumor cancers, we are a fully integrated company on the verge of a new era.

Our first commercial engineered T-cell therapy for solid tumors

On August 1, 2024, we received accelerated [FDA approval](#) for afamitresgene autoleucel (marketed as TECELRA®) for the treatment of adults with unresectable or metastatic synovial sarcoma who meet specific eligibility criteria. This approval made TECELRA the first FDA-approved engineered cell therapy for a solid tumor.

Our Pipeline

Adaptimmune is developing an industry-leading T cell therapy pipeline in solid tumors and has a deep pipeline of identified and proprietary targets for further product development. [See here](#) for more details about our strategically focused development pipeline.

About our Company

Adaptimmune is a fully integrated commercial-stage cell therapy company, designed and built from the ground up with UK- and U.S.-based biotechnology hub locations. In the U.S., locations are in Cambridge, MA and Philadelphia, PA. In the UK, locations are in Oxford and Stevenage. Our comprehensive capabilities and teams include preclinical research, clinical development, translational sciences, autologous and allogeneic manufacturing, and in-house commercial and corporate operations.

“Adaptimmune has the opportunity to deliver a range of cell therapies that would completely transform the way cancer is treated for a very broad population. And that opportunity, that vision to redefine how cancer is treated was really what drew me to lead this incredibly talented team.”



ADRIAN RAWCLIFFE
Chief Executive Officer



Who we are, how we behave and what we believe

Our culture is based on six core values:



BRAVE



COLLABORATIVE



HONEST



INCLUSIVE



TRUSTING



SUCCESSFUL

“Working at Adaptimmune is not a career, it’s a purpose. I am surrounded by intelligent and inspiring individuals working towards the same goal, in an environment that not only allows me to learn and grow, but also feel appreciated for my contributions”

—CAT BRANDON



Our Vision

Arming Cells. Against Cancer. For Good.

Our Mission

To Transform the Lives of People with Cancer by Designing and Delivering Cell Therapies

Chief Executive Officer

Adrian Rawcliffe

Locations

UNITED STATES

Philadelphia, PA
Navy Yard
351 Rouse Blvd
Philadelphia, PA,
19112
USA

Cambridge, MA
100 Binney St
Suite 710
Cambridge, MA,
02142
USA

UNITED KINGDOM

Milton Park
60 Jubilee Avenue,
Milton Park
Abingdon Oxfordshire
OX14 4RX
United Kingdom

Stevenage
4 Arlington Court
Arlington Business
Centre
Stevenage SG1 2FS
United Kingdom

www.adaptimmune.com